SCHEDULE: Venrock Group Cuts Cogent Biosciences Stake to 4.2%

A group of Venrock Healthcare Capital Partners entities and individuals have reduced their beneficial ownership in Cogent Biosciences, Inc. to 4.2% of common stock.

Summary

• Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Y. Koh (collectively, the "Reporting Persons") reported a beneficial ownership of 4,755,411 shares of Cogent Biosciences, Inc. Common Stock.
• This aggregate amount represents 4.2% of the Issuer's Common Stock outstanding.
• The percentage is based on 113,856,454 shares of Common Stock outstanding as of May 2, 2025, as reported in Cogent Biosciences' Quarterly Report on Form 10-Q filed on May 6, 2025.
• The Reporting Persons share both voting and dispositive power over all 4,755,411 shares.
• The ownership is distributed among the entities as follows: 740,049 shares by VHCP II, 299,719 shares by VHCP Co-Investment II, 2,084,386 shares by VHCP III, 208,591 shares by VHCP Co-Investment III, and 1,422,666 shares by VHCP EG.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in a significant institutional stake, which can be interpreted as a decrease in investor confidence, despite the explicit statement of no control intent.

Positives

• The Reporting Persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, indicating no immediate activist intent.

Negatives

• The beneficial ownership of the Reporting Persons has decreased to 4.2%, falling below the 5% threshold that typically triggers initial Schedule 13G filings, indicating a reduction in their stake in Cogent Biosciences, Inc.

Risks

• A reduction in a significant institutional investor's stake could be perceived by the market as a decrease in confidence in the company's future prospects or a strategic portfolio rebalancing by the investor.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The filing details a group of related entities (Venrock Healthcare Capital Partners funds and their management entities) and individuals (Nimish Shah and Bong Y. Koh, who are voting members of the management entities) acting as a group for beneficial ownership purposes.

Stakeholder Impact

• Shareholders may view the reduction in a significant institutional stake as a negative signal, potentially impacting investor sentiment and the company's stock price.
• The explicit statement that the shares are not held for control purposes may reassure current management and other shareholders regarding corporate stability.

Key Dates

Recommendation

The reduction in a significant institutional investor's stake to below 5% warrants a 'hold' recommendation. While not an immediate 'sell' signal without further context on the investor's rationale or the company's fundamentals, it suggests a potential decrease in institutional confidence or a portfolio rebalancing. Investors should monitor future filings and company performance closely.

Keywords

Cogent Biosciences, Venrock Healthcare Capital Partners, Schedule 13G, beneficial ownership, common stock, institutional investor, stake reduction